Eli Lilly scraps a tau program for Alzheimer’s, echoing past failures and casting doubt on entire approach
27 Oct 2021
During Tuesday’s third quarter earnings call with investors, Eli Lilly revealed it submitted its Alzheimer’s candidate donanemab for approval, using the same accelerated pathway charted by Biogen’s controversial Aduhelm. The pharma also said it would pit donanemab against Aduhelm head to head in a Phase III study, throwing down the gauntlet for a potentially multibillion dollar market.
But Lilly also disclosed an Alzheimer’s failure, noting an anti-tau program called zagotenemab missed the primary endpoint in a Phase II study, leading the company to scuttle development. Though CMO and CSO Dan Skovronsky said in opening remarks Lilly is still committed to researching tau, he took a decidedly different tack during the call’s question and answer session.
Organizations
Indications
-Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.